Morpholino-Driven Blockade of Dkk-1 in Osteosarcoma Inhibits Bone Damage and Tumor Expansion by Multiple Mechanisms

The authors indicated that administration of A vivo morpholino with or without chemotherapeutics could substantially improve osteosarcoma (OS) outcome with respect to tumor expansion and osteolytic corruption of bone in experimental OS model.